10 years Pivot Park: ImmunoPrecise
ImmunoPrecise’s core strength lies in its ability to quickly and efficiently adapt innovative antibody development technologies into novel therapies,” explains Debby Kruijsen who has been with the Pivot Park located company since 2012, first as a Researcher, now as General Manager.
InProcess-LSP finished with the best nine for The Dutch Innovation Award 2022
The Dutch Innovation Award is not only about innovation competencies, but also about the positive impact on people and the environment with its innovative technology.
Leaders in Life Sciences – #7 Paul Stoffels & Michel van Agthoven
Paul Stoffels is CEO van Galapagos en Michel van Agthoven is Lead Janssen Campus the Netherlands en director external affairs Netherlands bij Janssen.
LiteVax started Phase 1 trial with a novel, adjuvanted, low-dose influenza vaccine (TETRALITE)
Safety, tolerability, and immunogenicity of TETRALITE, a combination of 1/5th of a dose of a licensed influenza vaccine and the novel LiteVax Adjuvant, will be investigated in healthy subjects.
Kick-off of the second edition of the Surviving the Dutch program.
On September 28th the second edition of the Surviving the Dutch program started.
Leaders in Life Sciences – #6 Tom Oostrom
Tom Oostrom is directeur van de Nierstichting.
Leaders in Life Sciences – #5 Annemiek Verkamman
Annemiek Verkamman is directeur van HollandBIO.
Synaffix Wins ‘Best ADC Platform Technology’ Award Again at World ADC Awards Ceremony 2022
Synaffix announces that the Company was awarded ‘Best ADC Platform Technology’ at the World ADC Conference 2022.
Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal
Synaffix announced a $360M licensing agreement with Emergence Therapeutics, the 10th ADC developer to license their innovative ADC technology.
Acerta: Biggest biotech deal ever in the Netherlands
Pharmaceutical companies regularly come shopping in the Netherlands with a large bag of money. These pharmaceutical companies often buy the rights to a promising drug, and that’s always a bit of a gamble. An experimental drug is quickly promising, but the promise is not always fulfilled.
Innatoss enters partnership with Adaptics
Innatoss has entered into a great new partnership with Adaptics.
Leaders in Life Sciences – #4 Hanneke Schuitemaker
Hanneke Schuitemaker is Global Head of Viral Vaccine Discovery and Translational Medicine bij Janssen Pharmaceuticals.
or call
Pivot Park –
Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.
